WebAbstract Introduction: Tecovirimat (TPOXX®; ST-246) was approved for the treatment of symptomatic smallpox by the USFDA in July of 2024 and has been stockpiled by the US government for use in a smallpox outbreak. While there has not been a reported case of smallpox since 1978 it is still considered a serious bioterrorism threat. WebThis report features 14 companies, including Tonix Pharmaceuticals Holding, Gilead Sciences Inc., Marker Therapeutics Inc., Bavarian Nordic AS, Oncovir Inc., Emergent ...
Smallpox Treatment Market Size Projection by 2030
WebFDA approves drug to treat smallpox Disease considered eradicated in 1980 but drug development for smallpox is an important component for medical countermeasure … WebSmallpox treatment market size is estimated to grow by USD 66.1 million from 2024 to 2026 at a CAGR of 2% with the drugs having largest market share. Increasing stockpiling of smallpox therapeutics will be a key driver fueling the smallpox treatment growth during the forecast period. open wallet fresh start
Smallpox - Our World in Data
WebSmallpox is a highly contagious disease caused by the smallpox virus, an orthopoxvirus. Case fatality rate is about 30%. Natural infection has been eradicated. The main concern for outbreaks is from bioterrorism. Severe constitutional symptoms and a characteristic pustular rash develop. Treatment is generally supportive and potentially with ... WebNov 17, 2024 · In 2024, the U.S. Food and Drug Administration (FDA) approved the drug tecovirimat (TPOXX) to treat smallpox. The drug works by inhibiting the activity of a protein called p37, which ultimately... WebCDC. Thousands of years ago, variola virus (smallpox virus) emerged and began causing illness and deaths in human populations, with smallpox outbreaks occurring from time to time. Thanks to the success of … ipec for falls